트랜스티레틴 아밀로이드증 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Transthyretin Amyloidosis Treatment Market size is expected to reach USD 15.60 Million in 2034 from USD 7.32 Million (2025) growing at a CAGR of 8.77% during 2026-2034.

The Transthyretin Amyloidosis Treatment Market is poised for significant growth as awareness and diagnosis of this rare disease increase. Transthyretin amyloidosis (ATTR) is a progressive condition characterized by the accumulation of amyloid proteins in various tissues, leading to organ dysfunction. The rising prevalence of ATTR, particularly among aging populations, is driving the demand for effective treatment options. As healthcare providers seek to improve patient outcomes and quality of life, the market for ATTR treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the transthyretin amyloidosis treatment market. Innovations in drug development, including small molecule therapies and gene silencing techniques, are enhancing the efficacy of treatments aimed at reducing amyloid deposits and managing symptoms. Additionally, advancements in diagnostic tools are enabling earlier detection and more accurate monitoring of the disease, which is critical for timely intervention. As pharmaceutical companies continue to invest in research and development, the transthyretin amyloidosis treatment market is likely to see increased adoption of novel therapies and improved patient management strategies.

Moreover, the growing emphasis on patient-centered care and support is influencing the transthyretin amyloidosis treatment market's growth trajectory. As patients and their families become more informed about the disease and available treatment options, there is a rising demand for comprehensive care plans that address both medical and emotional needs. This trend is driving collaboration between healthcare providers, patient advocacy groups, and researchers to develop educational resources and support networks that empower patients in their treatment journey. As the market continues to evolve, the integration of technology, patient engagement, and holistic care approaches will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Tafamidis
• Patisiran
• Inotersen
• Others

By Diseases Type

• Hereditary Transthyretin Amyloidosis
• Wild Transthyretin Amyloidosis

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

COMPANIES PROFILED

• Pfizer Inc, AstraZeneca, Prothena Corporation plc, Ionis Pharmaceuticals, Bellus Health Inc, Alnylam Pharmaceuticals Inc, Eidos Therapeutics Inc, Som Biotech, Abbvie Inc, Bausch Health Companies Inc, Bristol Myers Squibb Company GSK Plc, Merck KGaA, Sanofi

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DRUG TYPE 2022-2034 (USD MN and Units)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Tafamidis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 4.3. Patisiran Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 4.4. Inotersen Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 5. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DISEASES TYPE 2022-2034 (USD MN and Units)

• 5.1. Market Analysis, Insights and Forecast Diseases Type
• 5.2. Hereditary Transthyretin Amyloidosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 5.3. Wild Transthyretin Amyloidosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 6. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY END USER 2022-2034 (USD MN and Units)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 6.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 6.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 7. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Units)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 7.3. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)
• 7.4. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN and Units)

Chapter 8. GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN and Units)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.2.1 By Drug Type
  • 8.2.2 By Diseases Type
  • 8.2.3 By End User
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.3.1 By Drug Type
  • 8.3.2 By Diseases Type
  • 8.3.3 By End User
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.4.1 By Drug Type
  • 8.4.2 By Diseases Type
  • 8.4.3 By End User
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.5.1 By Drug Type
  • 8.5.2 By Diseases Type
  • 8.5.3 By End User
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Units)
  • 8.6.1 By Drug Type
  • 8.6.2 By Diseases Type
  • 8.6.3 By End User
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer Inc
  • 10.2.2 AstraZeneca
  • 10.2.3 Prothena Corporation Plc
  • 10.2.4 Ionis Pharmaceuticals
  • 10.2.5 Bellus Health Inc
  • 10.2.6 Alnylam Pharmaceuticals Inc
  • 10.2.7 Eidos Therapeutics Inc
  • 10.2.8 Som Biotech
  • 10.2.9 Abbvie Inc
  • 10.2.10 Bausch Health Companies Inc
  • 10.2.11 Bristol Myers Squibb Company GSK Plc
  • 10.2.12 Merck KGaA
  • 10.2.13 Sanofi